Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Closed Date10/2012

General Information

Offices

South San Francisco, USA
400 Oyster Point Boulevard
Suite 108
South San Francisco, CA, 94080
USA

People

CEO
Chairman of the Board
CMO
Board Member
Board of Directors
Chairman

Funding

TOTAL $32.5M
FUNDING TOTAL $32.5M
Series A, 4/2010
Bay City Capital
Novo A/S
Canaan Partners
Life Science Angels
Atheneos Capital
$20M
Series A, 2/2012
Bay City Capital
Novo A/S
Canaan Partners
$12.5M

Tags

Altheos Closed down October, 2012

Altheos

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.

Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Recent Milestones

Videos

Screenshots

Sources

  1. Glaucoma drug focus inspires $20M A round for Altheos (fiercebiotech.com) [edit]
  2. Altheos grabs $12.5M more, launches glaucoma trial (fiercebiotech.com) [edit]
Edit This Page
Last Edited 11/19/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy